Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Traders are closely monitoring the upcoming Federal Reserve meeting, with high expectations for a rate hike as sentiment remains bearish amid concerns over rising Treasury yields, inflation, and oil price volatility. While some participants weigh the potential impact of AI development slowdowns and ongoing geopolitical tensions on market stability, the conversation remains largely focused on the Fed's policy trajectory and its influence on broader market performance.

The conversation is dominated by concerns over rising Treasury yields, which briefly topped 5%, alongside ongoing uncertainty regarding AI-sector development and expectations for a Federal Reserve rate hike. Market participants are debating whether current volatility represents a cooling phase or a potential crash, with a notable split between those reacting to macro headwinds and those betting on a continued market recovery.

Iovance Biotherapeutics is trending as traders speculate on positive guidance updates and clinical progress, following recent healthcare conference appearances and anticipation of upcoming Phase 2 NSCLC trial data. While the stock has seen significant momentum, community sentiment remains focused on the expectation that the company's solid tumor platform and clinical milestones will drive long-term value.

AppLovin shares are facing significant volatility as traders debate whether the stock is being manipulated by institutional accumulation or if macroeconomic headwinds and analyst price target downgrades are suppressing the price. The community remains divided, with many bullish investors holding for a recovery toward previous highs, while others express frustration over the stock's inability to maintain gains despite strong fundamentals and cash flow.

Traders are actively debating the viability of using UVXY as a volatility hedge amidst geopolitical tensions and economic concerns, with many expressing frustration over its structural decay and perceived lack of correlation to spot VIX. While some market participants are betting on a volatility spike, others warn that its design as a leveraged futures-based product makes it a poor long-term holding prone to constant value erosion.

Cisco is trending as investors discuss a newly announced partnership with Supermicro to integrate high-density rack-scale servers into the company's Secure AI Factory platform. While some traders are optimistic about the potential for enterprise AI growth, many others remain frustrated by the stock's recent stagnant price action and weak momentum following its earnings report.

IWM is experiencing volatility and downward pressure as traders weigh the impact of rising Treasury yields, higher oil prices, and uncertainty regarding Federal Reserve interest rate policy. The community is divided between those interpreting recent price action as a buying opportunity in a long-term uptrend and those concerned that the index is vulnerable to further downside, particularly given its technical weakness and sensitivity to macro headwinds.

TLT is trending as traders react to surging Treasury yields hitting multi-year highs and persistent concerns over inflation, oil prices, and the upcoming Federal Reserve interest rate decision. Market participants remain deeply divided on the outlook for long-term bonds, with many debating whether the current selloff presents a structural shift or a tactical buying opportunity.

BioNTech is trending as investors weigh clinical data updates on its oncology pipeline against the company's recent leadership transition, with some traders expressing disappointment over the upcoming departure of the founders while others remain optimistic about the late-stage trial catalysts.

Quantinuum's shares are experiencing volatility following its initial public offering as investors weigh the company's long-term potential in the quantum computing sector against concerns regarding its high valuation and lack of significant current revenue. While some traders are focused on the stock as a long-term play backed by strategic partners, others remain skeptical, citing broader market weakness and the company's early-stage financial profile.